Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Advanced Magnetics, Inc. To Present at the 32nd Annual Deutsche Bank Health Care Conference

Abstract:
Advanced Magnetics, Inc. (Nasdaq: AMAG), today announced that it will participate in
the 32nd annual Deutsche Bank Health Care conference, being held in
Washington D.C. on May 2-3, 2007. Brian J.G. Pereira, MD, President and
Chief Executive Officer of Advanced Magnetics, will present an overview of
the company on Wednesday, May 2, at 8:15 am ET.

Advanced Magnetics, Inc. To Present at the 32nd Annual Deutsche Bank Health Care Conference

Cambridge, MA | Posted on April 23rd, 2007

A live webcast of this presentation will be accessible through the
Investors section of the company's website at http://www.advancedmagnetics.com .
The event will also be archived on the Advanced Magnetics website for a
limited period of time following the conference.

####

About Advanced Magnetics, Inc.
Advanced Magnetics, Inc. is a developer of superparamagnetic iron oxide
nanoparticles used in pharmaceutical products. As a leader in our field, we
are dedicated to the development and commercialization of our proprietary
nanoparticle technology for use in therapeutic iron compounds to treat
anemia, as well as novel imaging agents to aid in the diagnosis of cancer
and cardiovascular disease.

Ferumoxytol, the company's key product candidate, is being developed
for use as an intravenous (IV) iron replacement therapeutic for the
treatment of iron deficiency anemia in chronic kidney disease. The company
plans to file a New Drug Application for marketing approval of ferumoxytol
with the U.S. Food and Drug Administration during the fourth calendar
quarter of 2007.

Combidex(R), the company's other product under development, is an
investigational functional molecular imaging agent consisting of iron oxide
nanoparticles for use in conjunction with MRI to aid in the differentiation
of cancerous from normal lymph nodes. In March 2005, the company received
an approvable letter from the FDA with respect to Combidex, subject to
certain conditions.

For more information, please click here

Contacts:
Kristen Galfetti

(617)498-3362

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Announcements

Searching for errors in the quantum world September 21st, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

UT engineers develop first method for controlling nanomotors: Breakthrough for nanotechnology as UT engineers develop first method for switching the mechanical motion of nanomotors September 21st, 2018

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

Events/Classes

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences August 31st, 2018

Stress-free ALD from Picosun August 28th, 2018

Kavli Lectures: New vision of nanomaterial synthesis and light-fueled space travel August 8th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project